Targeting CXCL12 to inhibit CXCR4 activation suppresses HCC cell proliferation, EMT, invasion, metastasis, and vasculogenic mimicry (VM) formation through the PI3K/Akt/NF-κB signaling pathway. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.